tiprankstipranks
Advertisement
Advertisement
Oragenics receives audit opinion with going concern explanation
PremiumThe FlyOragenics receives audit opinion with going concern explanation
4M ago
Oragenics files annual report on Form 10-K
Premium
The Fly
Oragenics files annual report on Form 10-K
4M ago
Oragenics initiates Phase IIa clinical trial site activation
Premium
The Fly
Oragenics initiates Phase IIa clinical trial site activation
4M ago
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
PremiumThe FlyOragenics partners with Duck Flats Pharma to support FDA IND trial design
6M ago
Oragenics Extends At-the-Market Equity Sales Agreement
Premium
Company Announcements
Oragenics Extends At-the-Market Equity Sales Agreement
6M ago
Oragenics files $100M mixed securities shelf
Premium
The Fly
Oragenics files $100M mixed securities shelf
6M ago
Oragenics Appoints Natasha Giordano to Board of Directors
PremiumCompany AnnouncementsOragenics Appoints Natasha Giordano to Board of Directors
11M ago
Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.
Premium
The Fly
Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.
11M ago
Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial
Premium
The Fly
Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100